Aarey Drugs & Pharmaceuticals Limited
NSE:AAREYDRUGS.NS
62.78 (INR) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 3,956.179 | 4,142.529 | 4,916.097 | 3,478.885 | 3,000.888 | 3,547.052 | 3,486.339 | 3,959.67 | 2,460.287 | 2,134.414 | 1,997.25 | 1,723.074 | 1,304.807 | 676.808 | 465.03 | 275.312 | 250.501 |
Cost of Revenue
| 3,843.15 | 4,038.407 | 4,720.649 | 3,377.902 | 2,901.816 | 3,409.728 | 3,373.639 | 3,829.882 | 2,430.291 | 2,102.666 | 1,963.366 | 1,688.517 | 1,276.083 | 654.214 | 452.267 | 247.645 | 231.805 |
Gross Profit
| 113.029 | 104.122 | 195.447 | 100.982 | 99.073 | 137.324 | 112.7 | 129.789 | 29.996 | 31.748 | 33.884 | 34.558 | 28.724 | 22.593 | 12.763 | 27.667 | 18.696 |
Gross Profit Ratio
| 0.029 | 0.025 | 0.04 | 0.029 | 0.033 | 0.039 | 0.032 | 0.033 | 0.012 | 0.015 | 0.017 | 0.02 | 0.022 | 0.033 | 0.027 | 0.1 | 0.075 |
Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 12.507 | 8.784 | 6.137 | 3.194 | 4.279 | 1.734 | 3.175 | 2.247 | 1.535 | 2.584 | 2.384 | 1.339 | 0 | 7.87 | 0 | 10.026 | 6.317 |
Selling & Marketing Expenses
| 1.706 | 11.325 | 3.891 | 1.618 | 2.073 | 2.164 | 2.94 | 7.191 | 2.94 | 0.508 | 8.245 | 7.471 | 0 | 0 | 0 | 1.15 | 0.625 |
SG&A
| 85.496 | 20.109 | 10.028 | 4.812 | 6.352 | 3.897 | 6.114 | 9.439 | 4.475 | 3.092 | 18.769 | 12.541 | 0 | 7.87 | 0 | 11.176 | 6.942 |
Other Expenses
| 69.649 | 74.327 | 5.848 | 45.82 | 40.249 | 22.356 | 2.916 | 81.831 | 19.173 | 27.07 | 25.108 | 18.601 | 17.52 | 3.492 | 3.24 | 4.744 | 4.426 |
Operating Expenses
| 85.496 | 89.627 | 100.867 | 63.735 | 75.522 | 68.325 | 39.863 | 91.269 | 23.647 | 27.07 | 25.108 | 18.601 | 17.52 | 11.362 | 3.24 | 15.92 | 11.368 |
Operating Income
| 27.533 | 66.92 | 100.265 | 82.305 | 63.538 | 91.292 | 72.837 | 79.784 | 18.13 | 14.1 | 13.41 | 9.025 | 4.111 | 9.955 | 9.511 | 11.45 | 7.328 |
Operating Income Ratio
| 0.007 | 0.016 | 0.02 | 0.024 | 0.021 | 0.026 | 0.021 | 0.02 | 0.007 | 0.007 | 0.007 | 0.005 | 0.003 | 0.015 | 0.02 | 0.042 | 0.029 |
Total Other Income Expenses Net
| 25.896 | -6.823 | 0.106 | 0.709 | 8.885 | -1.432 | 9.079 | 41.265 | 11.781 | 9.422 | 4.634 | -6.931 | -7.093 | -1.276 | -0.011 | -0.297 | 0 |
Income Before Tax
| 53.429 | 60.151 | 100.271 | 83.014 | 72.424 | 89.86 | 81.916 | 79.784 | 18.13 | 14.1 | 13.41 | 9.025 | 4.111 | 9.955 | 9.511 | 11.45 | 7.328 |
Income Before Tax Ratio
| 0.014 | 0.015 | 0.02 | 0.024 | 0.024 | 0.025 | 0.023 | 0.02 | 0.007 | 0.007 | 0.007 | 0.005 | 0.003 | 0.015 | 0.02 | 0.042 | 0.029 |
Income Tax Expense
| 6.592 | 22.386 | 34.823 | 17.871 | 14.488 | 24.442 | 20.14 | 20.966 | 5.236 | 3.216 | 2.9 | 2.443 | 1.273 | 2.05 | 1.406 | 2.4 | 2.569 |
Net Income
| 46.837 | 37.711 | 65.548 | 65.143 | 57.935 | 65.418 | 61.776 | 58.818 | 12.894 | 10.884 | 10.51 | 6.583 | 2.839 | 7.906 | 8.105 | 9.05 | 4.759 |
Net Income Ratio
| 0.012 | 0.009 | 0.013 | 0.019 | 0.019 | 0.018 | 0.018 | 0.015 | 0.005 | 0.005 | 0.005 | 0.004 | 0.002 | 0.012 | 0.017 | 0.033 | 0.019 |
EPS
| 1.84 | 1.49 | 2.72 | 2.79 | 2.48 | 2.8 | 2.64 | 3.03 | 0.77 | 0.65 | 0.63 | 0.39 | 0.2 | 1.32 | 1.35 | 1.29 | 0.79 |
EPS Diluted
| 1.84 | 1.49 | 2.72 | 2.79 | 2.48 | 2.8 | 2.64 | 3.03 | 0.77 | 0.65 | 0.63 | 0.39 | 0.2 | 1.32 | 1.35 | 1.29 | 0.79 |
EBITDA
| 44.513 | 104.56 | 139.514 | 115.464 | 98.392 | 121.366 | 107.401 | 102.109 | 40.504 | 36.94 | 14.996 | 21.735 | 17.1 | 16.274 | 14.195 | 16.491 | 11.754 |
EBITDA Ratio
| 0.011 | 0.025 | 0.028 | 0.033 | 0.033 | 0.034 | 0.031 | 0.026 | 0.016 | 0.017 | 0.008 | 0.013 | 0.013 | 0.024 | 0.031 | 0.06 | 0.047 |